Stockscreener 앱 받기
7.71
2.41%
-0.19
시간 외 거래:
7.71
전일 마감가:
$7.90
열려 있는:
$8.06
하루 거래량:
62,723
Relative Volume:
0.05
시가총액:
$69.47M
수익:
$23.14M
순이익/손실:
$-9.47M
주가수익비율:
-8.7346
EPS:
-0.8827
순현금흐름:
$-25.88M
1주 성능:
-7.00%
1개월 성능:
-26.64%
6개월 성능:
+38.67%
1년 성능:
-33.42%
1일 변동 폭
$7.65
$8.3305
1주일 범위
$7.65
$8.68
52주 변동 폭
$3.92
$19.14
아타라 Stock (ATRA) Company Profile
명칭
Atara Biotherapeutics Inc
전화
805-623-4211
주소
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
7.71 | 71.18M | 23.14M | -9.47M | -25.88M | -0.8827 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
아타라 Stock (ATRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-13 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-11-09 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-11-09 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-20 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2022-07-13 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-07-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-05-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-05-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-12-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-30 | 개시 | Evercore ISI | Outperform |
| 2020-06-15 | 개시 | H.C. Wainwright | Buy |
| 2020-04-23 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-11-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-09-27 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-09-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-06-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2019-05-30 | 개시 | ROTH Capital | Buy |
| 2019-05-23 | 개시 | Stifel | Buy |
| 2019-01-23 | 개시 | Mizuho | Buy |
| 2018-04-10 | 개시 | JP Morgan | Overweight |
| 2018-03-16 | 개시 | Guggenheim | Neutral |
| 2018-03-05 | 재확인 | Jefferies | Buy |
| 2018-02-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-01-03 | 업그레이드 | Citigroup | Sell → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
모두보기
아타라 주식(ATRA)의 최신 뉴스
Atara Biotherapeutics Inc (ATRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Atara Biotherapeutics Inc (ATRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Form 13D/A Atara Biotherapeutics For: 24 July By Investing.com - Investing.com South Africa
Form 4 Atara Biotherapeutics Inc For: 24 July By Investing.com - Investing.com South Africa
Atara Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:ATRA - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect - ACCESS Newswire
Redmile adjusts Atara Biotherapeutics (ATRA) ownership after warrant exercises - Stock Titan
ATRA|Atara Biotherapeutics Inc|Price:8.040|Chg%:-0.130 - TradingKey
Atara Biotherapeutics Inc (ATRA) Cash Flow - TradingKey
Atara Biotherapeutics Inc (ATRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Price to book forward of Atara Biotherapeutics, Inc. – NASDAQ:ATRA - TradingView
Avoiding Lag: Real-Time Signals in (ATRA) Movement - Stock Traders Daily
ATRA|Atara Biotherapeutics Inc|Price:8.089|Chg%:-0.081 - TradingKey
Price to sales forward of Atara Biotherapeutics Inc – SWB:AT20 - TradingView
Price to book forward of Atara Biotherapeutics Inc – SWB:AT20 - TradingView
Enterprise value to revenue forward of Atara Biotherapeutics Inc – SWB:AT20 - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect - ACCESS Newswire
Price to sales forward of Atara Biotherapeutics Inc – TRADEGATE:AT20 - TradingView
Enterprise value to EBITDA forward of Atara Biotherapeutics, Inc. – NASDAQ:ATRA - TradingView
2026-07-19 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect | NDAQ:ATRA | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biother - The National Law Review
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewi - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeuti - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
2026-07-14 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation | NDAQ:ATRA | Press Release - Stockhouse
Enterprise value to EBITDA forward of Atara Biotherapeutics Inc – MUN:AT20 - TradingView
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Enterprise value to EBIT forward of Atara Biotherapeutics Inc – MUN:AT20 - TradingView
Enterprise value to revenue forward of Atara Biotherapeutics Inc – MUN:AT20 - TradingView
ATRA FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - AOL.com
Atara Biotherapeutics Inc. (ATRA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
2026-07-09 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect | NDAQ:ATRA | Press Release - Stockhouse
ATRA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - AOL.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
2026-07-07 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation | NDAQ:ATRA | Press Release - Stockhouse
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Atara Biotherapeutics (ATRA) interim CFO Kevin Sarney files initial Form 3 - Stock Titan
Atara Biotherapeutics (ATRA) 10K Form and Latest SEC Filings 2026 - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation - ACCESS Newswire
Atara Biotherapeutics stock surges on FDA resubmission guidance By Investing.com - Investing.com Nigeria
ATRAAtara Biotherapeutics Inc Latest SEC Filings - Finviz
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out - ACCESS Newswire
ATRA Stockholders Have Opportunity to Lead Atara Biotherapeutics - The National Law Review
Discipline and Rules-Based Execution in ATRA Response - Stock Traders Daily
ATRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
ATRA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
아타라 (ATRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):